Spartan Metals Corp. (TSXV:W)

Revance Therapeutics Balance Sheet

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	0.01	0.03	0.08	0.14	0.18	0.02
Cash & Short-Term Investments	0.01	0.03	0.08	0.14	0.18	0.02
Cash Growth	-87.84%	-67.38%	-42.45%	-26.01%	767.29%	-66.84%
Other Receivables	0	0	0	0	0	0
Receivables	0	0	0	0	0	0
Prepaid Expenses	-	-	-	-	0	-
Total Current Assets	0.01	0.03	0.08	0.14	0.18	0.02
Total Assets	0.01	0.03	0.08	0.14	0.18	0.02
Accounts Payable	-	0.01	0.01	0.01	0.01	0.03
Accrued Expenses	-	-	-	-	0	0.15
Total Current Liabilities	-	0.01	0.01	0.01	0.01	0.19
Total Liabilities	-	0.01	0.01	0.01	0.01	0.19
Common Stock	14.37	14.37	14.37	14.37	14.37	13.95
Retained Earnings	-16.2	-16.19	-16.14	-16.08	-16.03	-15.95
Comprehensive Income & Other	1.84	1.84	1.84	1.84	1.84	1.84
Shareholders' Equity	0.01	0.02	0.07	0.13	0.18	-0.16
Total Liabilities & Equity	0.01	0.03	0.08	0.14	0.18	0.02
Net Cash (Debt)	0.01	0.03	0.08	0.14	0.18	0.02
Net Cash Growth	-87.84%	-67.38%	-42.45%	-26.01%	767.29%	-66.84%
Net Cash Per Share	0.00	0.00	0.00	0.01	0.01	0.00
Filing Date Shares Outstanding	23.47	16.47	16.47	16.47	16.47	12.27
Total Common Shares Outstanding	16.47	16.47	16.47	16.47	16.47	12.27
Working Capital	0.01	0.02	0.07	0.13	0.18	-0.16
Book Value Per Share	0.00	0.00	0.00	0.01	0.01	-0.01
Tangible Book Value	0.01	0.02	0.07	0.13	0.18	-0.16
Tangible Book Value Per Share	0.00	0.00	0.00	0.01	0.01	-0.01

Source: S&P Global Market Intelligence. Standard template. Financial Sources.